Authors
Latest:
Novel Treatment Strategies in Endometrial CancerClosing out their program on endometrial carcinoma management, key opinion leaders highlight key novel therapeutic strategies in the evolving treatment landscape.
Latest:
Bispecific Antibodies and ADCs Deliver a Futuristic Horizon Across Lung Cancer SettingsRecent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ivonescimab outperforming pembrolizumab in PD-L1-positive advanced non-small cell lung cancer.
Latest:
The Utility of CAPTEM in Chemo-Resistant Neuroendocrine TumorsRobert L. Fine, MD, from Columbia University, comments on the utility of CAPTEM in chemotherapy-resistant neuroendocrine tumors.
Latest:
The Development of the HER2-Specific Inhibitor ONT-380 for Breast CancerRobert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the development of ONT-380, an oral HER2-specific inhibitor, for the treatment of patients with HER2-positive metastatic breast cancer.
Latest:
An Analysis of the SWOG S0500 StudyRobert McCormack, PhD, head, Technology Innovation, Janssen Diagnostics, LLC, discusses the SWOG S0500 study, which evaluated different treatments in patients with metastatic breast cancer who had elevated circulating tumor cell (CTC) levels.
Latest:
Remaining Questions With Multiple Myeloma TreatmentRobert Orlowski, MD, PhD, Florence Maude Thomas Cancer Research professor and chair, ad interim, Department of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center, discusses remaining questions with multiple myeloma treatment.
Latest:
Development of Molecular Models Represents Significant Progress in Management of MedulloblastomaThe management of medulloblastoma, the most common malignant brain cancer in children, has not changed in decades but breakthroughs are on the horizon.
Latest:
Dr. Robert Z Orlowski on the Importance of the Phase III SWOG S0777 TrialData from the trial shows induction therapy with a triplet of bortezomib, lenalidomide, and dexamethasone improved both progression-free survival and overall survival over lenalidomide and dexamethasone alone in patients with untreated multiple myeloma.
Latest:
Identification of Patients With Luminal Androgen Receptor TNBCRoberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses the identification of patients with luminal androgen receptor (LAR) triple-negative breast cancer (TNBC) during the 2018 San Antonio Breast Cancer Symposium.
Latest:
First-Line Treatment Options for Patients with mCRCRoberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses first-line treatment options for advanced colorectal cancer (CRC).
Latest:
HDAC/mTOR Inhibitor Combination as Treatment for Prostate CancerRoberto Pili, MD, professor of oncology, chief, genitourinary section leader, Genitourinary Program, Department of Medicine, Roswell Park Cancer Center, discusses the possibility of using a HDAC/mTOR inhibitor combination as a treatment option for patients with prostate cancer.
Latest:
Dr. Robin Jones on Olaratumab and Doxorubicin Combination in Patients with Soft Tissue SarcomaRobin Jones, BSc, MB, MRCP, MD, oncologist, Royal Marsden Hospital, London, discusses the effectiveness of monoclonal antibody olaratumab in combination with doxorubicin in metastatic soft tissue sarcoma.
Latest:
Dr. Robin L. Jones on Eribulin Versus Dacarbazine in Patients With Leiomyosarcoma and Adipocytic SarcomaRobin L. Jones, BSc, MB, MRCP, MD, Consultant Oncologist, Royal Marsden Hospital, London, England, discusses results and takeaways from a phase III trial presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.
Latest:
Discussing Options for Ruxolitinib-Refractory Patients With MyelofibrosisRobyn M. Scherber, MD, MPH, discusses her advice for treating patients with myelofibrosis that become refractory or resistant to ruxolitinib.
Latest:
An Overview of Vigil Personalized Engineered Autologous Tumor Cells in Ovarian CancerRodney P. Rocconi, MD, chief of Gynecologic Oncology Service, associate director for Clinical Research, professor of Interdisciplinary Clinical Oncology, discusses a phase I trial of Vigil personalized engineered autologous tumor cells in ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.
Latest:
The Development of a Standardized Ki-67 AssayRodrigo Goncalves, MD, postdoctoral fellow, Washington University School of Medicine, discusses the development of a standardized Ki-67 assay.
Latest:
Novel Molecular Targets for Drug Development in Non-GIST SarcomasIn this review, Rodrigo R. Muhoz, MD, William D. Tap, MD, and Sandra P. D'Angelo, MD address the emerging therapeutic strategies aimed at specific molecular targets that could potentially change the approach to patients with soft-tissue sarcomas.
Latest:
Ancestral Progenitors in Glioblastoma Tumor RecurrenceRoeland GW Verhaak, PhD, assistant professor, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, discusses a study that examined the alteration of the p53 pathway and ancestral progenitors to determine if they were associated with tumor recurrence in glioblastoma.
Latest:
Adding TTFields to Chemotherapy to Improves Survival in GlioblastomaRoger Stupp, MD, discusses final results of a randomized, multi-center, phase III trial investigating tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma.
Latest:
Smoothened Inhibitors and the Hedgehog Pathway: Applications in Basal Cell Carcinoma and BeyondThe purpose of this article is to discuss the efficacy, indications for use, and safety of oral Hh pathway inhibitors for locally advanced BCC (LABCC) and for metastatic BCC (MBCC) through a review of the literature.
Latest:
Exploring the Use of MET Inhibition and Targeted Therapies in Lung CancerRoman Perez-Soler, MD, discusses the use of MET inhibitors as treatment of patients with lung cancer and the evolving role of targeted therapy in the lung cancer setting.
Latest:
Exploring Resistance to HER2-Targeted Therapy for Breast CancerRon Bose, MD, PhD, discusses the rationale for a trial of neratinib plus alpelisib for patients with HER2-positive breast cancer.
Latest:
A Study of Chemotherapy With Durvalumab and Tremelimumab in NSCLCRosalyn Juergens, MD, PhD, assistant professor, Department of Oncology, Division of Medical Oncology, McMaster University, discusses a clinical trial investigating chemotherapy with durvalumab and tremelimumab in patients with non-small cell lung cancer (NSCLC).
Latest:
The Various Risk Factors Associated With GliomaRose K. Lai, MD, clinical associate professor of Neurology, University of Southern California, discusses the many risk factors that can be associated with glioma.
Latest:
Multidisciplinary Approach Helps Determine Best Setting for Surgery in Metastatic Breast CancerRoss Mudgway, BS, explains how a multidisciplinary approach as well as open discussions with the patient can help determine the best course of action for patients with metastatic breast cancer.
Latest:
Breast Cancer PreventionRowan T. Chlebowski, MD, PhD, professor and chief, Harbor-University of California Los Angeles Medical Center, Department of Internal Medicine, Medical Oncology/Hematology, discusses breast cancer prevention.
Latest:
SBRT in Surgery for Patients With Early NSCLCRoy Decker, MD, PhD, associate professor of therapeutic radiology, assistant professor of surgery (Otolaryngology), Clinical Research Program Leader, Therapeutic Radiology, Yale University, discusses stereotactic body radiation therapy (SBRT) in surgery for patients with early non-small cell lung cancer (NSCLC).
Latest:
Combination Immunotherapy for Treatment of Lung CancerRoy S. Herbst, MD, PhD, Yale Cancer Center, discusses the use of combination immunotherapy for the treatment of lung cancer.
